Kuros Biosciences AG (KURN) - Net Assets

Latest as of June 2025: CHF76.65 Million CHF ≈ $96.91 Million USD

Based on the latest financial reports, Kuros Biosciences AG (KURN) has net assets worth CHF76.65 Million CHF (≈ $96.91 Million USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CHF109.97 Million ≈ $139.03 Million USD) and total liabilities (CHF33.32 Million ≈ $42.12 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Kuros Biosciences AG (KURN) asset resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CHF76.65 Million
% of Total Assets 69.7%
Annual Growth Rate -1.54%
5-Year Change -30.56%
10-Year Change 8681.46%
Growth Volatility 1316.08

Kuros Biosciences AG - Net Assets Trend (2004–2024)

This chart illustrates how Kuros Biosciences AG's net assets have evolved over time, based on quarterly financial data. Also explore Kuros Biosciences AG assets under control for the complete picture of this company's asset base.

Annual Net Assets for Kuros Biosciences AG (2004–2024)

The table below shows the annual net assets of Kuros Biosciences AG from 2004 to 2024. For live valuation and market cap data, see Kuros Biosciences AG (KURN) market capitalisation.

Year Net Assets Change
2024-12-31 CHF58.75 Million
≈ $74.27 Million		 +3.59%
2023-12-31 CHF56.71 Million
≈ $71.70 Million		 -17.64%
2022-12-31 CHF68.86 Million
≈ $87.06 Million		 -10.54%
2021-12-31 CHF76.98 Million
≈ $97.32 Million		 -9.01%
2020-12-31 CHF84.60 Million
≈ $106.96 Million		 +8.66%
2019-12-31 CHF77.86 Million
≈ $98.43 Million		 +1.79%
2018-12-31 CHF76.48 Million
≈ $96.70 Million		 +4.57%
2017-12-31 CHF73.14 Million
≈ $92.47 Million		 +90.86%
2016-12-31 CHF38.32 Million
≈ $48.45 Million		 +5628.25%
2015-12-31 CHF669.00K
≈ $845.80K		 +102.55%
2014-12-31 CHF-26.22 Million
≈ $-33.15 Million		 -719.86%
2013-12-31 CHF4.23 Million
≈ $5.35 Million		 -57.82%
2012-12-31 CHF10.03 Million
≈ $12.68 Million		 +185.86%
2011-12-31 CHF-11.68 Million
≈ $-14.77 Million		 -277.10%
2010-12-31 CHF6.59 Million
≈ $8.34 Million		 -19.97%
2009-12-31 CHF8.24 Million
≈ $10.42 Million		 -74.13%
2008-12-31 CHF31.86 Million
≈ $40.28 Million		 -41.47%
2007-12-31 CHF54.43 Million
≈ $68.82 Million		 +18.59%
2006-12-31 CHF45.90 Million
≈ $58.03 Million		 -37.98%
2005-12-31 CHF74.01 Million
≈ $93.57 Million		 -7.69%
2004-12-31 CHF80.17 Million
≈ $101.36 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Kuros Biosciences AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 4393700000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock CHF3.79 Million 6.45%
Other Comprehensive Income CHF26.39 Million 44.92%
Other Components CHF74.00 Million 125.96%
Total Equity CHF58.75 Million 100.00%

Kuros Biosciences AG Competitors by Market Cap

The table below lists competitors of Kuros Biosciences AG ranked by their market capitalization.

Company Market Cap
TWO HARBORS INV. DL-0001
F:2H2
 $989.19 Million
Pacira BioSciences, Inc.
NASDAQ:PCRX
 $989.57 Million
Preformed Line Products Company
NASDAQ:PLPC
 $989.86 Million
Gracell Biotechnologies Inc.
NASDAQ:GRCL
 $989.87 Million
Cymbria Corporation
TO:CYB
 $987.87 Million
Chongqing Lummy Pharmaceutical
SHE:300006
 $987.34 Million
Queclink Wireless Solutions Co Ltd
SHE:300590
 $987.30 Million
Hana Materials Inc
KQ:166090
 $986.95 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Kuros Biosciences AG's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 56,712,000 to 58,748,000, a change of 2,036,000 (3.6%).
  • Net loss of 3,716,000 reduced equity.
  • Share repurchases of 2,387,748 reduced equity.
  • New share issuances of 1,941,000 increased equity.
  • Other comprehensive income increased equity by 4,501,000.
  • Other factors increased equity by 1,697,748.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CHF-3.72 Million -6.33%
Share Repurchases CHF2.39 Million -4.06%
Share Issuances CHF1.94 Million +3.3%
Other Comprehensive Income CHF4.50 Million +7.66%
Other Changes CHF1.70 Million +2.89%
Total Change CHF- 3.59%

Book Value vs Market Value Analysis

This analysis compares Kuros Biosciences AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 12.84x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 0.01x to 12.84x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2004-12-31 CHF1464.04 CHF20.28 x
2005-12-31 CHF1199.65 CHF20.28 x
2006-12-31 CHF720.67 CHF20.28 x
2007-12-31 CHF840.46 CHF20.28 x
2008-12-31 CHF488.78 CHF20.28 x
2009-12-31 CHF126.34 CHF20.28 x
2010-12-31 CHF101.09 CHF20.28 x
2011-12-31 CHF-179.01 CHF20.28 x
2012-12-31 CHF49.93 CHF20.28 x
2013-12-31 CHF14.63 CHF20.28 x
2014-12-31 CHF-74.52 CHF20.28 x
2015-12-31 CHF0.17 CHF20.28 x
2016-12-31 CHF6.19 CHF20.28 x
2017-12-31 CHF8.33 CHF20.28 x
2018-12-31 CHF7.47 CHF20.28 x
2019-12-31 CHF4.53 CHF20.28 x
2020-12-31 CHF3.48 CHF20.28 x
2021-12-31 CHF2.35 CHF20.28 x
2022-12-31 CHF2.03 CHF20.28 x
2023-12-31 CHF1.55 CHF20.28 x
2024-12-31 CHF1.58 CHF20.28 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Kuros Biosciences AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -6.33%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -4.92%
  • • Asset Turnover: 0.89x
  • • Equity Multiplier: 1.44x
  • Recent ROE (-6.33%) is above the historical average (-29.99%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2004 -29.75% -580.01% 0.05x 1.10x CHF-31.87 Million
2005 -38.48% -653.51% 0.05x 1.11x CHF-35.88 Million
2006 -75.28% -4772.38% 0.01x 1.25x CHF-39.14 Million
2007 -12.63% -19.16% 0.29x 2.27x CHF-12.32 Million
2008 -81.64% -131.87% 0.18x 3.48x CHF-29.20 Million
2009 -301.25% -272.57% 0.13x 8.34x CHF-25.65 Million
2010 -22.05% -6.51% 0.41x 8.20x CHF-2.11 Million
2011 0.00% -1195.35% 0.05x 0.00x CHF-17.61 Million
2012 -91.89% -837.82% 0.04x 3.03x CHF-10.22 Million
2013 -728.75% -3082.60% 0.02x 9.57x CHF-31.25 Million
2014 0.00% -3402.60% 0.06x 0.00x CHF-31.40 Million
2015 930.79% 97.99% 1.95x 4.87x CHF6.16 Million
2016 -51.52% -1860.89% 0.02x 1.14x CHF-23.58 Million
2017 -22.54% -3086.89% 0.01x 1.18x CHF-23.80 Million
2018 -15.29% -1635.38% 0.01x 1.12x CHF-19.34 Million
2019 -14.45% -439.36% 0.03x 1.13x CHF-19.04 Million
2020 -13.62% -285.22% 0.04x 1.12x CHF-19.98 Million
2021 -9.80% -54.59% 0.15x 1.19x CHF-15.24 Million
2022 -21.20% -81.15% 0.22x 1.20x CHF-21.48 Million
2023 -24.20% -40.90% 0.47x 1.26x CHF-19.40 Million
2024 -6.33% -4.92% 0.89x 1.44x CHF-9.59 Million

Industry Comparison

This section compares Kuros Biosciences AG's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $214,981,672
  • Average return on equity (ROE) among peers: 8.71%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Kuros Biosciences AG (KURN) CHF76.65 Million -29.75% 0.43x $988.78 Million
Medartis Holding AG (MED) $-46.95 Million 0.00% 0.00x $1.17 Billion
Medacta Group SA (MOVE) $330.04 Million 14.35% 1.11x $3.06 Billion
Sonova H Ag (SOON) $361.86 Million 11.78% 1.05x $10.75 Billion

About Kuros Biosciences AG

SW:KURN Switzerland Medical Devices
Market Cap
$1.00 Billion
CHF794.48 Million CHF
Market Cap Rank
#9167 Global
#119 in Switzerland
Share Price
CHF20.28
Change (1 day)
-3.43%
52-Week Range
CHF20.28 - CHF33.36
All Time High
CHF36.96
Categories
Companies in Switzerland Medical Devices
About

Kuros Biosciences AG engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally. It operates through two segments, Medical Devices and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technol… Read more